This might provide a biologic explanation for the persistence of PD-L1-positive CTCs in NSCLC patients after six months of treatment, predicting resistance to the anti-PD-1 Nivolumab shown by Nicolazzo and colleagues [30]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.